Etoricoxib CAS 202409-33-4 Purity ≥99.0% (HPLC) Factory

Short Description:

Chemical Name: Etoricoxib

CAS: 202409-33-4

Purity: ≥99.0% (HPLC)

Appearance: White to Off-White Powder

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

202409-33-4 - Description:

Ruifu Chemical is the leading manufacturer of Etoricoxib (CAS: 202409-33-4) with high quality. Etoricoxib is widely used in the treatment of osteoarthritis (OA), acute gouty arthritis, and etc. Ruifu Chemical has been supplying pharmaceutical intermediates and APIs more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service. Purchase Etoricoxib, Please contact: alvin@ruifuchem.com

Intermediates of Etoricoxib (CAS: 202409-33-4):

Etoricoxib API	CAS 202409-33-4
4-(Methylthio)phenylacetic Acid	CAS 16188-55-9
4-(Methylsulfonyl)phenylacetic Acid	CAS 90536-66-6
Methyl 6-Methylnicotinate	CAS 5470-70-2
1-(6-Methylpyridin-3-yl)-2-[4-(Methylthio)phenyl]ethanone	CAS 221615-72-1
1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone	CAS 221615-75-4
2-Chloro-1,3-Bis(dimethylamino)trimethinium Hexafluorophosphate	CAS 249561-98-6 ; 291756-76-8

202409-33-4 - Chemical Properties:

Chemical Name	Etoricoxib
Synonyms	5-Chloro-6'-Methyl-3-[4-(Methylsulfonyl)phenyl]-2,3'-Bipyridine; 5-Chloro-3-[4-(Methylsulfonyl)phenyl]-2-(2-Methyl-5-Pyridinyl)pyridine; MK-0663; MK0663; L-791456; Arcoxia
Stock Status	In Stock, Commercial Production
CAS Number	202409-33-4
Molecular Formula	C18H15ClN2O2S
Molecular Weight	358.84 g/mol
Melting Point	133.0 to 137.0℃
Density	1.298±0.06 g/cm3
Store Under Inert Gas	Store Under Inert Gas
Sensitive	Air Sensitive, Heat Sensitive
Solubility	Soluble in DMSO, and Methanol
Storage Temp.	Store Under Inert Gas (Nitrogen or Argon) at 2~8℃
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	API (Active Pharmaceutical Ingredient)
Caution	Not Intended for Human Use. For Research Use Only.
Brand	Ruifu Chemical

202409-33-4 - Specifications:

Items	Specifications	Results
Appearance	White to Off-White Powder	Off-White Powder
Melting Point	133.0~137.0℃	134.0~135.0℃
Loss on Drying	<0.50%	0.12%
Residue on Ignition	<0.20%	0.05%
Heavy Metals (Pb)	<20ppm	<10ppm
Etoricoxib Purity	≥99.0% (HPLC)	99.7%
Infrared Spectrum	Conforms to Structure	Conforms
NMR Spectrum	Conforms to Structure	Conforms
Conclusion	The product has been tested and complies with the given specifications

202409-33-4 - Package/Storage/Shipping:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.

202409-33-4 - Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

202409-33-4 - FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

202409-33-4 - Risk and Safety:

Hazard Symbols T - Toxic
Risk Codes R22 - Harmful if swallowed
R24 - Toxic in contact with skin
Safety Description S36/37 - Wear suitable protective clothing and gloves.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
UN IDs UN 2811 6.1 / PGII
WGK Germany 3

202409-33-4 - Application:

Etoricoxib (CAS: 202409-33-4) is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company. Etoricoxib has a unique chemical structure that is methylsulfonyl group. The introduction of this group can not only increase the selectivity for COX-2 drugs, but also does not produce sulfa drugs and cross-allergic reactions.
Etoricoxib was first approved for entering into market in 2002 in the UK, followed by the marketing countries and regions including the European Union, Asia, Australia and Latin America. Until the end of 2013, it has been approved for marketing in 97 countries for being widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases.
Etoricoxib has also entered into market in Taiwan and Hong Kong of China. It had entered into market in Chinese mainland in 2008 with the approved indications being acute gouty arthritis and OA and another indication being primary dysmenorrhea in the second half year of 2014.